Rilpivirine impurities include process-related compounds, synthetic intermediates, degradation products, and nitrosamine contaminants that may arise during synthesis, formulation, or storage. As a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.
Pharmacopeial and non-pharmacopeial Rilpivirine impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials include nitrile isomers, amide derivatives, and halogenated analogs, supplied with validated analytical data including purity, structural confirmation, and spectral characterization.
Structurally related compounds and synthetic analogs associated with Rilpivirine are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.
Rilpivirine impurity reference standards are provided with validated analytical data including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
